BioRestorative Therapies (BRTX) Common Equity (2010 - 2025)
BioRestorative Therapies' (BRTX) quarterly Common Equity came in at $356744.0 in Q4 2025, down 95.82% YoY from $8.5 million in Q4 2024, and down 83.84% on a QoQ basis from $2.2 million in Q3 2025.
BioRestorative Therapies (BRTX) Common Equity (2010 - 2025) Analysis & Trends
BioRestorative Therapies (BRTX) has 16 years of Common Equity data on file, last reported at $356744.0 in Q4 2025.
- Quarterly Common Equity fell 95.82% year-over-year to $356744.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $356744.0 (down 95.82% YoY) and the FY2025 annual result came in at $356744.0, down 95.82% from the prior year.
- Common Equity retreated to $356744.0 in Q4 2025, from $2.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $14.5 million in Q1 2024 to a low of -$4.9 million in Q3 2021.
- A 5-year average of $6.2 million and a median of $7.5 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2021 — Common Equity soared 909.82% — and 2025, when it tumbled 95.82%.
- Tracing BRTX's Common Equity over 5 years: stood at $10.8 million in 2021, then decreased by 4.57% to $10.3 million in 2022, then slipped by 2.78% to $10.0 million in 2023, then dropped by 14.72% to $8.5 million in 2024, then plunged by 95.82% to $356744.0 in 2025.
- The last three Common Equity figures came in at $356744.0 (Q4 2025), $2.2 million (Q3 2025), and $4.8 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | BioRestorative Therapies | 2.00 Mn | -953,752.60 | 17,964.00 | 356,744.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 356,744.00 |
| Sep 30, 2025 | 2.21 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | 6.14 Mn |
| Dec 31, 2024 | 8.53 Mn |
| Sep 30, 2024 | 9.99 Mn |
| Jun 30, 2024 | 10.80 Mn |
| Mar 31, 2024 | 14.50 Mn |
| Dec 31, 2023 | 10.00 Mn |
| Sep 30, 2023 | 10.76 Mn |
| Jun 30, 2023 | 2.64 Mn |
| Mar 31, 2023 | 6.46 Mn |
| Dec 31, 2022 | 10.29 Mn |
| Sep 30, 2022 | 9.78 Mn |
| Jun 30, 2022 | 12.16 Mn |
| Mar 31, 2022 | 5.95 Mn |
| Dec 31, 2021 | 10.78 Mn |
| Sep 30, 2021 | -4.88 Mn |
| Jun 30, 2021 | -3.81 Mn |
| Mar 31, 2021 | -2.69 Mn |